Retrospective Study
Copyright ©The Author(s) 2021.
World J Gastrointest Oncol. Jul 15, 2021; 13(7): 706-715
Published online Jul 15, 2021. doi: 10.4251/wjgo.v13.i7.706
Table 1 Patient demographics
Clinicopathologic features
Value (%)
Mean age (range), yr51.3 ± 13.1 (30-84)
Sex, male/female
Male19 (68)
Female9 (32)
Tumor location
Bulb2 (7)
Descending section16 (57)
Horizontal section9 (32)
Ascending section1 (4)
Surgical technique
Open surgery13 (46)
Robotic surgery15 (54)
Types of resection
Limited resection17 (61)
PD11 (39)
Tumor size (cm)
≤ 22 (7)
2-517 (61)
5-107 (25)
> 102 (7)
Risk assessment (NIH 2008)
Low19 (68)
Medium5 (18)
High4 (14)
Resection margin status
R028 (100)
R10
Postoperative targeted drug therapy
Yes9 (32)
No19 (68)
Postoperative recurrence and metastasis
Yes4 (14)
No24 (86)
Table 2 Comparison of patients in the open surgery group and robotic surgery group (n = 28)

No. of patients
P value
Open
Robotic
Total patients1315
Age0.718
≥ 50 yr88
< 50 yr57
Sex0.689
Male811
Female54
Tumor size0.255
< 5 cm510
≥ 5 cm85
Surgical technique0.700
Limited resection710
PD65
OT (min)0.029
mean ± SD 1207.7 ± 63.1156.0 ± 55.4
EBL (mL)0.01
mean ± SD 1340.0 ± 401.862.3 ± 34.9
PHS (d)0.294
mean ± SD 116 ± 9.415.7 ± 13.4
Mitotic count (/50 HPF)1.000
≤ 51214
> 511
Risk assessment0.072
Low613
Medium41
High31
POPC1.000
Yes77
No68
Postoperative targeted therapy1.000
Yes45
No910
Recurrence/metastasis0.311
Yes31
No1014
Table 3 General information on patients with recurrence and metastasis (n = 4)
Patient, No./sex/age, yr
Tumor location
Operation
Recurrent time (mo)
Recurrent location
Risk of disease progression
1/M/75Descending sectionRPD21LiverMedium
2/M/61Horizontal sectionPD36MesocolonHigh
3/M/50Descending sectionPD108LiverMedium
4/M/56Descending sectionPD60LiverMedium